Insulet (NASDAQ: PODD) reported Q4 EPS of $0.08, $0.03 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $209.4 million versus the consensus estimate of $199.5 million.

• Fourth quarter 2019 revenue of $209.4 million, up 27% compared to $164.9 million in the prior year, exceeds guidance of $193 to $201 million
  • Total Omnipod revenue of $192.5 million, an increase of 30%
    • U.S. Omnipod revenue of $126.7 million, an increase of 36%
    • International Omnipod revenue of $65.8 million, an increase of 20%
  • Drug Delivery revenue of $16.9 million, an increase of 1%
• Gross margin of 64.0%, down 290 basis points
• Operating income of $18.2 million compared to $16.2 million in the prior year
• Net income of $5.0 million, or $0.08 per diluted share, compared to $9.9 million, or $0.16 per share, in the prior year

"2019 was a remarkable year for Insulet, marked by disciplined execution of our strategy that allowed us to deliver consistent financial outperformance and strong operational results," said Shacey Petrovic, President and Chief Executive Officer. "With a solid foundation, pipeline of innovative technologies and proven strategy firmly in place, we made progress investing across our global organization to drive sustainable, long-term growth. As we look ahead to 2020, Insulet has a clear trajectory to strengthen our leadership position and make even greater treatment options a reality for the large and underserved global diabetes market. We are well on track to meet our 2021 financial targets of $1 billion in revenue, 70% gross margin and mid-teens operating margin, and remain focused on advancing our mission to ease the burden of people living with diabetes."

For earnings history and earnings-related data on Insulet (PODD) click here.